Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection.

Brunelli SM, Van Wyck DB, Njord L, Ziebol RJ, Lynch LE, Killion DP.

J Am Soc Nephrol. 2018 Apr;29(4):1336-1343. doi: 10.1681/ASN.2017080870. Epub 2018 Feb 22.

PMID:
29472415
2.

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.

Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Cronin M, Meier Y, Larroque S, Macdougall IC; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1530-1539. doi: 10.1093/ndt/gfw264.

3.

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.

Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC.

PLoS One. 2016 Jun 8;11(6):e0157063. doi: 10.1371/journal.pone.0157063. eCollection 2016.

4.

Knowing what we do and doing what we should: quality assurance in hemodialysis.

Alquist M, Bosch JP, Barth C, Combe C, Daugirdas JT, Hegbrant JB, Martin G, McIntyre CW, O'Donoghue DJ, Rodriguez HJ, Santoro A, Tattersall JE, Vantard G, Van Wyck DB, Canaud B.

Nephron Clin Pract. 2014;126(3):135-43. doi: 10.1159/000361050. Epub 2014 Apr 15.

PMID:
24751758
5.

Within-patient variation of hemoglobin and reticulocytes: implications for evaluating ESA responsiveness in dialysis patients.

Van Wyck DB, Giles I, Sharpe K.

Int J Lab Hematol. 2012 Dec;34(6):577-83. doi: 10.1111/j.1751-553X.2012.01435.x. Epub 2012 Jun 6.

PMID:
22672348
6.

Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis.

Van Wyck DB, Alcorn H Jr, Gupta R.

Am J Kidney Dis. 2010 Sep;56(3):540-6. doi: 10.1053/j.ajkd.2010.05.009. Epub 2010 Jul 16.

PMID:
20638166
7.

Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.

Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT.

Transfusion. 2009 Dec;49(12):2719-28. doi: 10.1111/j.1537-2995.2009.02327.x. Epub 2009 Jul 22.

PMID:
19682342
8.

Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.

Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB; United States Iron Sucrose (Venofer) Clinical Trials Group.

Clin J Am Soc Nephrol. 2006 May;1(3):475-82. Epub 2006 Mar 29.

9.

Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.

Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A.

Obstet Gynecol. 2007 Aug;110(2 Pt 1):267-78. Erratum in: Obstet Gynecol. 2008 Apr;111(4):996.

PMID:
17666600
10.

A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD.

Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S; United States Iron Sucrose (Venofer) Clinical Trials Group.

Kidney Int. 2005 Dec;68(6):2846-56.

11.

Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients.

Walters BA, Van Wyck DB.

Nephrol Dial Transplant. 2005 Jul;20(7):1438-42. Epub 2005 Apr 19.

PMID:
15840683
12.

Making sense: a scientific approach to intravenous iron therapy.

Van Wyck DB, Danielson BG, Aronoff GR.

J Am Soc Nephrol. 2004 Dec;15 Suppl 2:S91-2. No abstract available.

13.

Labile iron: manifestations and clinical implications.

Van Wyck DB.

J Am Soc Nephrol. 2004 Dec;15 Suppl 2:S107-11. Review. No abstract available.

14.

Error, not iron, generates cytotoxicity.

Van Wyck DB.

Am J Kidney Dis. 2002 Nov;40(5):1109-10; author reply 1110. No abstract available.

PMID:
12407664
15.

Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease.

Van Wyck DB, Bailie G, Aronoff G.

Am J Kidney Dis. 2002 Feb;39(2):426-32. No abstract available.

PMID:
11840388
16.

Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.

Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB.

Am J Kidney Dis. 2001 Feb;37(2):300-7.

PMID:
11157370
17.

Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy.

Van Wyck DB.

Nephrol Dial Transplant. 2000;15 Suppl 3:36-9. Review.

PMID:
11032356
18.

Lessons from NKF-DOQI: iron management.

Van Wyck DB.

Semin Nephrol. 2000 Jul;20(4):330-4. Review. No abstract available.

PMID:
10928334
19.

Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.

Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N.

Am J Kidney Dis. 2000 Jul;36(1):88-97.

PMID:
10873877
20.

Erythropoietin level and effect of rHuEPO in beta-thalassemic mice.

Popp RA, Shinpock SG, Qopp DM, Clemons GK, Van Wyck DB.

Ann N Y Acad Sci. 1998 Jun 30;850:455-8. No abstract available.

PMID:
9668582
21.

Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents.

Roe DJ, Harford AM, Zager PG, Wiltbank TB, Kirlin L, Della Valle AM, Van Wyck DB.

Am J Kidney Dis. 1996 Dec;28(6):855-60.

PMID:
8957037
22.

Impact of erythropoietin on the dialysis prescription.

Van Wyck DB.

Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):71-5. Review.

PMID:
1928083
23.

Iron management during recombinant human erythropoietin therapy.

Van Wyck DB.

Am J Kidney Dis. 1989 Aug;14(2 Suppl 1):9-13.

PMID:
2757026
24.

Resistance to infection in murine beta-thalassemia.

Ampel NM, Van Wyck DB, Aguirre ML, Willis DG, Popp RA.

Infect Immun. 1989 Apr;57(4):1011-7.

26.

Iron status in patients receiving erythropoietin for dialysis-associated anemia.

Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA.

Kidney Int. 1989 Feb;35(2):712-6.

27.

Coccidioidal peritonitis associated with continuous ambulatory peritoneal dialysis.

Ampel NM, White JD, Varanasi UR, Larwood TR, Van Wyck DB, Galgiani JN.

Am J Kidney Dis. 1988 Jun;11(6):512-4.

PMID:
3376935
28.

Rapid sample preparation for determination of iron in tissue by closed-vessel digestion and microwave energy.

Van Wyck DB, Schifman RB, Stivelman JC, Ruiz J, Martin D.

Clin Chem. 1988 Jun;34(6):1128-30.

29.

Iron homeostasis in beta-thalassemic mice.

Van Wyck DB, Tancer ME, Popp RA.

Blood. 1987 Nov;70(5):1462-5.

30.

Splenomimetic effect of Corynebacterium parvum in fulminant pneumococcemia.

Wellish KL, Witte MH, Witte CL, Van Wyck DB, Kinter KV, Hagaman RM.

J Infect Dis. 1987 Jul;156(1):130-5.

PMID:
3598214
31.

Compensatory spleen growth and protective function in rats.

Van Wyck DB, Witte MH, Witte CL.

Clin Sci (Lond). 1986 Nov;71(5):573-9.

PMID:
3769406
32.

Immunoarchitecture of the regenerating rat spleen: effects of partial splenectomy and heterotopic autotransplantation.

Dugan MC, Grogan TM, Witte MH, Rangel C, Richter L, Witte CL, Van Wyck DB.

Scan Electron Microsc. 1986;(Pt 2):607-13.

PMID:
3541150
33.

Spontaneous iron overload in alpha-thalassemic mice.

Van Wyck DB, Popp RA, Foxley J, Witte MH, Witte CL, Crosby WH.

Blood. 1984 Jul;64(1):263-6.

34.

LeVeen shunt endocarditis.

Van Wyck DB, Witte MH, Witte CL, Friedman MJ, Macbeth AG.

Arch Intern Med. 1984 Apr;144(4):868-9. No abstract available.

PMID:
6712391
35.

Preservation of the spleen.

Witte MH, Witte CL, Van Wyck DB, Farrell KJ.

Lymphology. 1983 Jun;16(2):128-37.

PMID:
6887971
36.

Overwhelming postsplenectomy infection (OPSI): the clinical syndrome.

Van Wyck DB.

Lymphology. 1983 Jun;16(2):107-14.

PMID:
6887968
37.

Clinical disorders of splenic function: the spectrum from asplenism to hypersplenism.

Corrigan JJ Jr, Van Wyck DB, Crosby WH.

Lymphology. 1983 Jun;16(2):101-6.

PMID:
6887967
38.

Ischaemia and partial resection for control of splenic hyperfunction.

Witte CL, Van Wyck DB, Witte MH, Corrigan JJ Jr, Zukoski CF, Pond GD, Woolfenden JM.

Br J Surg. 1982 Sep;69(9):531-5. No abstract available.

PMID:
7104650
39.

Synergism between the spleen and serum complement in experimental pneumococcemia.

Van Wyck DB, Witte MH, Witte CL.

J Infect Dis. 1982 Apr;145(4):514-9.

PMID:
7069232
40.

Critical splenic mass for survival from experimental pneumococcemia.

Van Wyck DB, Witte MH, Witte CL, Thies AC Jr.

J Surg Res. 1980 Jan;28(1):14-7. No abstract available.

PMID:
7359904
41.

Circulatory control of splenic hyperfunction in children with peripheral blood dyscrasia.

Witte CL, Corrigan JJ Jr, Witte MH, Van Wyck DB, O'Mara RE, Woolfenden JM.

Surg Gynecol Obstet. 1980 Jan;150(1):75-80.

PMID:
7350706
42.

Humoral immunity in experimental hyposplenism.

Van Wyck DB, Witte MH, Witte CL, Strunk RC.

Surgery. 1978 Jul;84(1):134-9.

PMID:
307280
43.

Antibody formation by subcutaneous and omental splenic autotransplants in rats.

Bowman CA, Van Wyck DB, Witte MH, Witte CL.

J Am Med Womens Assoc (1972). 1977 Nov;32(11):409-13, 419. No abstract available.

PMID:
200644
44.

Immune function in disorders of the lymph circulation.

van Wyck DB, Lucas DO.

Vasc Surg. 1977 May-Jun;11(3):152-9. No abstract available.

PMID:
616692
45.

Ischemic therapy in thrombocytopenia from hypersplenism.

Witte CL, Ovitt TW, Van Wyck DB, Witte MH, O'Mara RE, Woolfenden JM.

Arch Surg. 1976 Oct;111(10):1115-21.

PMID:
987762

Supplemental Content

Loading ...
Support Center